All In Biotech

Drug Trial Radar · NCT03731260

(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis

A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy

Last checked: Nov 20, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 251 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

251

Actual

Start

Apr 16, 2019

Primary completion

Jun 23, 2027

Study completion Jun 23, 2027

Sponsor

Sponsor type
Industry
First posted
Nov 6, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of avapritinib + best supportive care (BSC) with placebo + BSC in patients with indolent systemic mastocytosis (ISM) whose symptoms are not adequately controlled by BSC. The study will be conducted in 3 parts. All patients will receive treatment with avapritinib during Part 3 including those rolling over from the placebo group.

Conditions

  • Indolent Systemic Mastocytosis

Interventions

  • AvapritinibDrug

    Avapritinib tablet

  • PlaceboDrug

    Placebo tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Recommended Phase 2 dose (RP2D) in patients with ISMTime frame: 9 months
  2. Part 2: Mean change in ISM Symptom Assessment Form (ISM-SAF) total symptom score (TSS) as compared to placeboTime frame: 6 months
  3. Part 3: Number of Participants with Adverse EventsTime frame: Up to 5 years

Locations

49 sites in 13 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Mayo Clinic Hospital

    Phoenix, Arizona

  • Stanford Cancer Institute

    Stanford, California

  • Mayo Clinic Florida

    Jacksonville, Florida

  • H. Lee Moffitt Cancer Center

    Tampa, Florida

  • Winship Cancer Institute, Emory University

    Atlanta, Georgia

  • Rush University Medical Center

    Chicago, Illinois

  • University of Kansas Hospital

    Kansas City, Kansas

  • Brigham & Women's Hospital

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Michigan Medicine, University of Michigan

    Ann Arbor, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • Herbert Irving Comprehensive Cancer Center

    New York, New York

  • Duke University Health System (DUHS)

    Durham, North Carolina

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • University of Texas, MD Anderson Cancer Center

    Houston, Texas

  • Huntsman Cancer Institute

    Salt Lake City, Utah

  • Virginia Commonwealth University Medical Center

    Richmond, Virginia

  • University Hospital Antwerp

    Edegem, Belgium

  • Tom Baker Cancer Centre

    Calgary, Alberta, Canada

  • University of Alberta Hospital

    Edmonton, Alberta, Canada

  • St. Michael's Hospital

    Toronto, Ontario, Canada

  • Odense Universitetshospital, ORCA/Allergicentret, Hudafdeling I og Allergicenter

    Odense, Denmark

  • Hôpital de la Timone, Service de dermatologie

    Marseille, France

  • Hôpital Pitié-Salpêtrière, Service de Dermatologie

    Paris, France

  • CHU Toulouse Larrey, CEREMAST, Service de Dermatologie et Allergologie cutanée

    Toulouse, France

  • Uniklinik RWTH Aachen

    Aachen, Germany

  • Charité Universitätsmedizin Berlin

    Berlin, Germany

  • University Clinic Hamburg Eppendorf, University Cancer Center Hamburg (UCCH)

    Hamburg, Germany

  • Universitätsklinikum Schleswig-Holstein, Hämatologie/Onkologie

    Lübeck, Germany

  • Universitätsklinik Mainz, Universitäts-Hautklinik, Clinical Research Center

    Mainz, Germany

  • Universitätsmedizin Mannheim, III. Medizinische Klinik

    Mannheim, Germany

  • Klinikum rechts der Isar, Technische Universität München

    Munich, Germany

  • A.O.U di Bologna - IRCCS, Istituto di Ematologia Lorenzo e Ariosto Seragnoli, Ematologia

    Bologna, Italy

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Poloclinico, UOC Ematologia

    Milan, Italy

  • A.O. OO.RR. S.Giovanni di Dio e Ruggi d'Aragona, University of Salerno

    Salerno, Italy

  • Azienda Ospedaliera Universitaria Integrata di Verona

    Verona, Italy

  • University Medical Center Groningen (UMCG)

    Groningen, Netherlands

  • Erasmus Medical Center

    Rotterdam, Netherlands

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.